Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut

INTERPACE BIOSCIENCES, INC.

2023-Q2 EPS reported -$1.47 revenue$4,410,000

Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.
Adjusted EBITDA $(2.9)M vs $(0.3)M; gross margin 37% vs 48% due to 70% retroactive ThyGeNEXT price cut.
Cash balance fell to $1.9M at June 30 from $3.8M year ago; DSO improved 15% to 59 days.
Launched Point2Glucose test; YTD net loss improved $1.5M to $(6.1)M; new thyroid data published.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.